UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

Hepatology (Baltimore, Md.), 2005-09, Vol.42 (3), p.724-731

2005

Volltextzugriff (PDF)

Hydroxy-methylglutaryl-coenzyme a reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance

Circulation (New York, N.Y.), 2001-01, Vol.103 (1), p.113-118

2001

Volltextzugriff (PDF)

Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein e-/-mice in vivo

Circulation (New York, N.Y.), 2003-05, Vol.107 (19), p.2480-2486

2003

Volltextzugriff (PDF)

Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase

The Journal of clinical investigation, 1999-03, Vol.103 (6), p.897-905

1999

Volltextzugriff (PDF)

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations

British journal of clinical pharmacology, 2003-12, Vol.56 (6), p.653-657

2003

Volltextzugriff (PDF)

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors

Clinical pharmacokinetics, 1996-11, Vol.31 (5), p.348-371

1996

Volltextzugriff (PDF)

Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites

Clinical pharmacology and therapeutics, 2003-03, Vol.73 (3), p.178-191

2003

Volltextzugriff (PDF)

Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress

Clinical pharmacology and therapeutics, 1998-08, Vol.64 (2), p.144-149

1998

Volltextzugriff (PDF)

Dietary oligofructose lowers triglycerides, phospholipids and cholesterol in serum and very low density lipoproteins of rats

Lipids, 1995-02, Vol.30 (2), p.163-167

1995

Volltextzugriff (PDF)

CYP3A4 activity in four different animal species liver microsomes using 7-benzyloxyquinoline and HPLC/spectrofluorometric determination

Journal of pharmaceutical and biomedical analysis, 2006-01, Vol.40 (1), p.211-214

2006

Volltextzugriff (PDF)

Oxidative stress, KLF6 and transforming growth factor-β up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats

Journal of hepatology, 2003-10, Vol.39 (4), p.538-546

2003

Volltextzugriff (PDF)

Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation

Journal of hepatology, 1998-03, Vol.28 (3), p.410-416

1998

Volltextzugriff (PDF)

Serum beta-carotene in anorexia nervosa patients: A case-control study

The International journal of eating disorders, 2001-11, Vol.30 (3), p.299-305

2001

Volltextzugriff (PDF)

Alfentanil-Induced Miosis Clearance as a Liver CYP3A4 and 3A5 Activity Measure in Healthy Volunteers: Improvement of Experimental Conditions

Journal of clinical pharmacology, 2005-12, Vol.45 (12), p.1434-1441

2005

Volltextzugriff (PDF)

Estimation of chlorzoxazone hydroxylase activity in liver microsomes and of the plasma pharmacokinetics of chlorzoxazone by the same high-performance liquid chromatographic method

Journal of Chromatography A, 1998-12, Vol.828 (1), p.291-296

1998

Volltextzugriff (PDF)

Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days

Atherosclerosis, 1996-07, Vol.124, p.S65-S73

1996

Volltextzugriff (PDF)

Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines

Clinical pharmacokinetics, 1995-05, Vol.28 (5), p.419-432

1995

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers

Clinical pharmacology and therapeutics, 1997-03, Vol.61 (3), p.325-330

1997

Volltextzugriff (PDF)

Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis

Clinical pharmacokinetics, 2007-01, Vol.46 (3), p.261-270

2007

Volltextzugriff (PDF)

Clinical pharmacokinetics of ticlopidine

Clinical pharmacokinetics, 1994-05, Vol.26 (5), p.347-355

DESAGER, J.-P

1994

Volltextzugriff (PDF)

Absolute bioavailability of amiodarone in normal subjects

Clinical pharmacology and therapeutics, 1985-02, Vol.37 (2), p.118-123

1985

Volltextzugriff (PDF)

Dietary restriction of energy and sugar results in a reduction in human cytochrome P450 2E1 activity

British journal of nutrition, 1999-10, Vol.82 (4), p.257-262

1999

Volltextzugriff (PDF)

Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase

The Journal of clinical investigation, 1999-03, Vol.103 (6), p.897-905

1999

Volltextzugriff (PDF)

Uricosuric Effect of Fenofibrate in Healthy Volunteers

Journal of clinical pharmacology, 1980-10, Vol.20 (10), p.560-564

1980

Volltextzugriff (PDF)

D-propoxyphene and norpropoxyphene kinetics after the oral administration of D-propoxyphene: a new approach to liver function?

Journal of hepatology, 1994-09, Vol.21 (3), p.283-291

1994

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(34)
Science & Technology
(34)
Humans
(30)
Biological And Medical Sciences
(29)
Medical Sciences
(27)
Male
(22)
Pharmacology. Drug Treatments
(20)
Pharmacology & Pharmacy
(18)
Adult
(17)
Female
(16)
Animals
(11)
Middle Aged
(8)
Rats
(7)
Cytochrome P-450 Enzyme System - Metabolism
(6)
General Pharmacology
(6)
Administration, Oral
(5)
Aged
(5)
Cytochrome P-450 Cyp3a
(5)
Dose-Response Relationship, Drug
(5)
Gastroenterology. Liver. Pancreas. Abdomen
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

Hydroxy-methylglutaryl-coenzyme a reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance

Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein e-/-mice in vivo

Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors

Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites

Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress

Dietary oligofructose lowers triglycerides, phospholipids and cholesterol in serum and very low density lipoproteins of rats

CYP3A4 activity in four different animal species liver microsomes using 7-benzyloxyquinoline and HPLC/spectrofluorometric determination

Oxidative stress, KLF6 and transforming growth factor-β up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats

Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation

Serum beta-carotene in anorexia nervosa patients: A case-control study

Alfentanil-Induced Miosis Clearance as a Liver CYP3A4 and 3A5 Activity Measure in Healthy Volunteers: Improvement of Experimental Conditions

Estimation of chlorzoxazone hydroxylase activity in liver microsomes and of the plasma pharmacokinetics of chlorzoxazone by the same high-performance liquid chromatographic method

Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days

Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines

Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers

Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis

Clinical pharmacokinetics of ticlopidine

Absolute bioavailability of amiodarone in normal subjects

Dietary restriction of energy and sugar results in a reduction in human cytochrome P450 2E1 activity

Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase

Uricosuric Effect of Fenofibrate in Healthy Volunteers

D-propoxyphene and norpropoxyphene kinetics after the oral administration of D-propoxyphene: a new approach to liver function?

Suchergebnisse filtern